Looks like Amgen might not be buying Alexion after all. Instead, it’s beefing up in psoriasis, where it already sells blockbuster TNF inhibitor Enbrel, by snatching up Celgene’s Otezla for $13.4 billion.
(Bloomberg) — Amgen Inc. will pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp., which is shedding the asset in order to win antitrust regulators’ sign-off for its $74 billion merger with Bristol-Myers Squibb Co.The all-cash deal will give Amgen a growing product at a time when the
Amid a turbulent year, Kraft Heinz announced Monday that it will replace its young chief financial officer with the “seasoned veteran” who held the role before him. David Knopf, who was 29 and the youngest high-ranking executive at the company when he assumed the CFO role in 2017, will leave the processed food giant.
US must unite at home before it can realistically face up to Beijing
Kraft Heinz said Paulo Basilio will take over as chief financial officer, a role he previously held at H.J. Heinz and at Kraft Heinz after the merger.
Here comes Beyond Meat plant-based fried chicken at KFC.
Starbucks will being selling a Pumpkin Cream Cold Brew drink for the first time. That’s in addition to the hot Pumpkin Spice Latte, which has attracted a cult following for the company.
Amgen will buy the psoriasis pill Otezla from Celgene, which is selling it to remove an obstacle from its planned merger with Bristol-Myers Squibb.
Ecstacy or blasphemy? You can decide for yourself starting on Tuesday.
Last week US President Donald Trump announced plans to wide-ranging tariff increases in response to news of retaliatory tariffs from Beijing.
